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Background & aims: In recent years, obesity has reached alarming levels among children and adoles-
cents. The study of plasma fatty acid (FA) composition, as a reflection of diet, and its associations with
other parameters, that are closely linked to obesity and the cardiometabolic profile, may be useful for
setting nutritional goals for obesity treatment and prevention. This study explored the relationship
between plasma FA levels and body fat and cardiometabolic risk markers, in overweight adolescents.
Methods: A multidisciplinary weight loss program was followed by 127 overweight and obese adoles-
cents aged 12e17 years old. Plasma FA composition, anthropometric indicators of adiposity and
biochemical parameters were analyzed at baseline, two months (the end of the intensive intervention
phase) and six months (the end of the extensive phase).
Results: While saturated fatty acid (SFA) and n-6 polyunsaturated fatty acid (PUFA) levels decreased
significantly during the intervention, monounsaturated fatty acid (MUFA) and n-3 PUFA showed the
opposite trend. The decrease in SFA C14:0 was associated with a reduction in total and LDL cholesterol,
apolipoprotein B and insulin. The increase in MUFAs, especially C18:1n-9, was related to a reduction in
weight, fat mass, fat mass index and glucose. Regarding PUFAs, changes in the n-3 series were not
associated with any of the parameters studied, whereas the reduction in n-6 PUFAs was directly related
to weight, fat mass, total and HDL cholesterol, apolipoprotein A1, glucose and insulin, and inversely
associated with diastolic blood pressure. The adolescents with greater weight loss presented significant
changes in MUFAs, n-6 PUFAs and C14:0.
Conclusions: Modifications in plasma FA composition were associated with adiposity reduction and
cardiometabolic profile improvement in an anti-obesity program aimed at adolescents. The changespolipoprotein B; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular diseases; DBP, diastolic blood
taenoic acid; FA, fatty acid; HDL, high-density lipoprotein; LA, linoleic acid; LC-PUFA, long-chain polyunsaturated fatty
aturated fatty acids; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; SDS-BMI,
acids; TAG, triacylglycerols; VLDL, very-low-density lipoprotein.
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j.clnu.2016.11.006observed in FA composition were related to the success of the treatment, since the individuals most
affected by these variations were those who presented the greatest weight loss.





























































Obesity in early life has become a matter of concern for health
organizations worldwide, since it is an extremely prevalent disor-
der in developed countries and is reaching alarming values in
developing countries [1]. Being overweight is a key risk factor for
several disorders, especially cardiovascular disease (CVD), but also
type-2 diabetes, dyslipidemia and inflammation [2]. The relation-
ship between obesity and other diseases in children and adoles-
cents has been investigated at length [3]. It has been found that
obese children present a higher degree of oxidative stress and
systemic inflammation than their normal-weight counterparts.
Dietary and multidisciplinary interventions may induce changes in
this metabolic and inflammatory state [4].
In obese people, the fatty acid (FA) composition of blood and
tissue changes and affects some important physiological functions
related to body fat. Overweight adolescents have higher levels of
saturated fatty acids (SFAs) [5] and lower levels of mono-
unsaturated fatty acids (MUFAs) [6], docosahexaenoic acid
(C22:6n-3, DHA) and total n-3 polyunsaturated fatty acids (PUFAs)
[5] than normal-weight adolescents. The FA composition of plasma
lipids reflects dietary fat intake. Thus, diet and lifestyle in-
terventions may be effective in preventing the development of
obesity and associated disorders [7].
Several studies have established that an elevated intake of SFA
has adverse effects on health, since they cause white adipose tissue
expansion, increase oxidative stress and inflammation, impair in-
sulin signaling and cause insulin resistance in multiple tissues [8].
By contrast, MUFA consumption reduces adipocyte size [9] and
lipogenesis by increasing FA oxidation [7]. Thus, populations with
high oleic acid (C18:1 n-9) intake, such as the Mediterranean diet,
have a lower prevalence of obesity, type-2 diabetes and cardio-
vascular events [10]. It has been suggested that palmitoleic acid
(16:1 n-7), other MUFA, has hormone-like properties and improves
some metabolic parameters that are impaired in obesity and type 2
diabetes mellitus; however, the results in plasma are still unclear
[11].
It has been observed that PUFAs participate in themodulation of
several pathways involved in lipoprotein metabolism, thereby
influencing blood cholesterol andminimizing insulin resistance [7].
Studies in animals and humans supplemented with n-3 FAs have
shown an improvement in insulin sensitivity and a reduction in the
secretion of very-low-density lipoprotein (VLDL), apoB degradation
and FA oxidation [7]. In addition, dietary n-3 PUFAs are associated
with lower levels of inflammation and endothelial activation in
cardiovascular disease and other chronic and acute diseases [12].
The present study explored the associations between anthro-
pometric and cardiometabolic parameters and plasma fatty acid
levels in overweight and obese adolescents subjected to a multi-
disciplinary anti-obesity program. The evolution of these parame-
ters was evaluated at different points in the intervention and the
degree of weight loss achieved by the last period taken into ac-
count. To our knowledge, this is the first study to analyze plasma
fatty acid composition according to degree of weight loss in over-
weight and obese adolescents. Therefore, this trial may be very
useful to develop more complete studies to establish dietary re-
gimes aimed at reduce the prevalence of pediatric obesity and
associated pathologies.in M, et al., Changes in plasm
eutic approach to overweig2. Materials and methods
2.1. Ethics statement
Written informed consent was obtained from all adolescents
and their parents. The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki (Hong Kong revi-
sion,1989; Edinburgh revision, 2000; and Seoul revision, 2008), the
European Economic Community (EEC) Good Clinical Practice
guidelines (document 111/3976/88 of July 1990) and current
Spanish law, which regulates clinical research on humans (Royal
Decree 561/1993 on clinical trials). This project was also approved
by the local ethics committees.
2.2. Participants and study design
The study comprised 127 adolescents aged 12e17 years old and
diagnosed as overweight or obese at four hospitals in various
Spanish cities (Granada, Madrid, Pamplona and Zaragoza). The in-
clusion criteria were as follows: overweight or obese, Spanish or
educated in Spain, and free from any other diagnosed disease.
Adolescents receiving pharmacological treatment or diagnosed
with anorexia, bulimia or any other eating disorder, except binge-
eating disorder, were excluded. The individuals included were
treated as part of the EVASYON Study (development, imple-
mentation and evaluation of the efficacy of a therapeutic program
for overweight and obese adolescents: comprehensive education
on nutrition and physical activity). It comprised a calorie-restricted
diet (10e40%), increased physical activity (at least 60 min/day, 5
days a week), psychological therapy and nutritional education. The
macronutrient distribution was as follow: 50% of energy from car-
bohydrates, 30% from fat and 20% from proteins.
2.3. Dietary intake and physical condition
The study group previously validated 72-h dietary record and a
semi-quantitative food-frequency questionnaire, which were
applied to assess dietary intake of adolescents. The nutrient con-
sumption was determined using the latest available information in
food-composition tables from Spain.
Physical Activity Questionnaire for Adolescents (PAQ-A), Course
navette or 20-m Shuttle run test, Handgrip strength and 4  10-m
shuttle-run, among others tests and questionnaires were used to
evaluate the physical activity.
2.4. Body composition, pubertal development and resting blood
pressure
The anthropometric measures used in this study were height,
weight and skin-fold thicknesses (triceps, biceps, subscapular,
suprailiac, thigh and calf), which were measured consecutively in
triplicate and averaged. Body mass index was calculated as weight
(kg)/height (m2). Body weight was determined without shoes and
with light clothing using a standard beam balance. Skin-fold
thicknesses were measured on the left side of the body using a
Holtain skin-fold calliper.
Pubertal development was assessed in accordance with the 5-
stage system established by Tanner, and blood pressure wasa fatty acid composition are associated with improvements in obesity
ht adolescents, Clinical Nutrition (2016), http://dx.doi.org/10.1016/
Table 1
Population characteristics and measurements of clinical and biochemical parame-
ters, physical condition and dietary intake at baseline.
Characteristics N Values
Sex, male (%) 127 44.5
Age (years) 127 14.16 ± 1.18






Weight (kg) 106 85.7 ± 1.66
BMI (kg/m2) 106 31.4 ± 0.49
SDS-BMI 106 2.80 ± 0.05
Waist circumference (cm) 97 99.0 ± 1.24
Body fat (%) 93 35.8 ± 0.47
Body fat (kg) 92 30.8 ± 0.80
FMI (kg/m2) 90 11.2 ± 0.28
FFM (%) 93 64.2 ± 0.47
Systolic blood pressure (mm Hg) 80 123.4 ± 1.60
Diastolic blood pressure (mm Hg) 80 72.6 ± 1.29
Biochemical parameters
Glucose (mmol/L) 97 4.63 ± 0.04
Insulin (mUI/mL) 20 18.8 ± 3.00
Cholesterol (mmol/L) 106 4.01 ± 0.06
HDL-cholesterol (mmol/L) 104 1.15 ± 0.03
LDL-cholesterol (mmol/L) 104 2.34 ± 0.06
Triacylglycerol (mmol/L) 106 1.01 ± 0.05
Apolipoprotein A1 (mg/dL) 73 117.14 ± 2.16
Apolipoprotein B (mg/dL) 73 69.93 ± 2.06
ApoB/apoA1 ratio 73 0.62 ± 0.19
C-reactive protein (mg/L) 58 3.26 ± 0.43
Physical condition
Hand grip strength (Kg) 107 29.12 ± 7.78
Agility (seconds) 106 13.62 ± 1.53
Cardiorespiratory endurance (periods) 98 3.07 ± 1.52
Dietary intake
Energy (Kcal/d) 113 3336.87 ± 1613.99
Carbohydrates (g/d) 113 362.9 ± 181.09
Proteins (g/d) 113 130.81 ± 59.27
Lipids (g/d) 113 151.04 ± 84.42
Total fiber (g/d) 113 27.05 ± 13.01
Results expressed in mean ± SEM values. BMI, body mass index; SDS-BMI, standard
deviation score of BMI; FMI, fat mass index; FFM, fat free mass; ApoB/apoA1 ratio,
apolipoprotein B/apolipoprotein A1 ratio.



































































































































YCLNU2972_proof ■ 15 November 2016 ■ 3/8obtained using a digital automatic blood pressure monitor (Omron
M6, Omron Health Care Co., Ltd., Kyoto, Japan) according to vali-
dated procedures.
2.5. Biochemical and metabolic analysis
Blood was collected by venepuncture, after an overnight fast,
and then was centrifuged. The aliquots of plasma or serum were
stored at 80 C until analysis.
Total cholesterol, HDL cholesterol, triacylglycerols (TAG),
glucose and C-reactive protein (CRP) were determined using an
Olympus AU2700 biochemical autoanalyser (Olympus, Melville, NY,
USA). VLDL cholesterol and low-density lipoprotein (LDL) choles-
terol were calculated from existing values for cholesterol, HDL
cholesterol and triglycerides. Apolipoprotein B (apoB) and A1
(apoA1) and insulin were analyzed by Luminex-100 IS (Integrated
System: Luminex Corporation, Austin, TX, USA).
2.6. Determination of plasma fatty acids
Plasma fatty acid levels were determined at three different pe-
riods: before the treatment started, at two months of intervention
and at six months of treatment. Analyses were carried out by fast
gas chromatography according to the method developed in our
laboratory by Bondía-Pons et al. [13]. One hundred microliters of
plasma samples were saponified by adding sodium methylate and
heating to 100 C. After cooling, the samples were esterified with
boron trifluoride-methanol reagent (at the same temperature).
Once the tubes were cooled, fatty acid methyl esters were isolated
by adding n-hexane. A saturated sodium chloride solutionwas then
added. Finally, the tubes were centrifuged and, after drying with
anhydrous sodium sulfate, the clear n-hexane top layer was
transferred to an automatic injector vial. Fast gas chromatography
analyses were performed on a Shimadzu GC-2010 Gas Chromato-
graph (Shimadzu, Kyoto, Japan). The injection volume of the sample
was 1 mL. The injector and detector temperatures were kept at
250 C and 270 C, respectively. The identities of sample methyl
ester peaks were determined by comparing their relative retention
times with those of well-known fatty acid methyl esters standards.
Quantification was performed by standard normalization.
2.7. Statistical analysis
Results are presented as means ± standard deviation (SD) or
standard error of the mean (SEM). SPSS 20.0 (SPSS Inc., Chicago, IL,
USA) was used for statistical analyses. The KolmogoroveSmirnov
test was used to assess the distribution of variables. Changes in
clinical or biochemical parameters and plasma fatty acid compo-
sition were analyzed by general linear models using the Bonferroni
post-hoc correction. To evaluate the relationship between changes
in plasma fatty acids and variations in anthropometric indicators of
adiposity, blood pressure and biochemical parameters at two and
six months of the intervention, linear regression models were
applied. The models were adjusted for age, sex, standard deviation
score of body mass index (SDS-BMI) and Tanner stages at baseline,
changes in lipid and energy intake at six months with respect to the
baseline, and the degree of physical activity. It should be noted that
the correlations were only analyzed for those variables that
changed significantly between each intervention period and the
baseline. General linear models were also applied to examine the
differences between changes in fatty acid composition and clinical
and biochemical parameters at six months of the intervention in
the different weight loss groups, with control for potential con-
founding factors (sex, age, SDS-BMI, Tanner stage and the corre-
sponding variable at baseline, degree of physical activity andPlease cite this article in press as: Guerendiain M, et al., Changes in plasm
and related metabolic disorders: A therapeutic approach to overweig
j.clnu.2016.11.006changes in lipid and energy intake at six months with respect to the
baseline). To determine whether the changes in the parameters
analyzed were significant in each weight loss group, estimated
marginal means were used. For all analyses, two-sided significance
was determined at P < 0.05.
3. Results
The characteristics of the population at baseline are given in
Table 1, which also includes anthropometric and biochemical
measurements, physical condition and dietary intake. These data
were also obtained at two and six months of the intervention. A
more detailed study of the evolution of these parameters was
published previously [14]. The differences detected in those results
have been taken into account to establish the correlations with
plasma FA changes.
Table 2 shows plasma FA composition along the intervention
period. During the intensive phase, i.e., the first two months, SFA
C14:0 (myristic acid) and C18:0 (stearic acid) decreased signifi-
cantly (p < 0.01), while total MUFAs and, especially, oleic acid
presented the opposite trend (p < 0.001). The sum of plasma PUFAs
decreased in the first period and remained constant until the end of
the intervention (p < 0.05). Among PUFAs, two different behaviors
were observed at two months, depending on the series to whicha fatty acid composition are associated with improvements in obesity
ht adolescents, Clinical Nutrition (2016), http://dx.doi.org/10.1016/
Table 2








SFA (%) 29.96 ± 2.14 29.77 ± 1.99 29.52 ± 1.49 0.676
C14:0 0.59 ± 0.25a 0.47 ± 0.15b 0.50 ± 0.19a,b 0.001
C15:0 0.14 ± 0.03 0.13 ± 0.03 0.14 ± 0.03 0.433
C16:0 22.06 ± 1.70a,b 22.62 ± 1.52a 22.21 ± 1.63b 0.039
C17:0 0.22 ± 0.36 0.21 ± 0.03 0.22 ± 0.03 0.054
C18:0 6.96 ± 0.74a 6.31 ± 0.66b 6.45 ± 0.74b 0.004
MUFA (%) 23.30 ± 3.11a 24.28 ± 2.91b 24.28 ± 2.95b <0.001
C16:1 n-7 1.34 ± 0.43a,b 1.37 ± 0.37a 1.26 ± 0.40b 0.031
C18:1 n-9 21.85 ± 2.92a 22.94 ± 2.84b 22.89 ± 2.75b <0.001
C20:1 n-9 0.11 ± 0.03a 0.11 ± 0.03a 0.13 ± 0.03b 0.012
PUFA (%) 46.74 ± 4.04a 45.96 ± 3.83b 46.14 ± 3.56b 0.013
C20:3 n-9 0.09 ± 0.03a 0.08 ± 0.02b 0.09 ± 0.02b 0.025
n-6 43.80 ± 4.03a 42.56 ± 3.88b 43.03 ± 3.71b 0.004
C18:2 n-6 33.83 ± 3.86a 32.97 ± 3.47b 33.16 ± 3.56b 0.021
C20:2 n-6 0.18 ± 0.05a 0.16 ± 0.04b 0.17 ± 0.04a,b 0.009
C18:3 n-6 0.34 ± 0.12a 0.27 ± 0.11b 0.29 ± 0.09b 0.002
C20:3 n-6 1.60 ± 0.37a 1.27 ± 0.32b 1.41 ± 0.35c 0.032
C20:4 n-6 7.36 ± 1.42 7.51 ± 1.51 7.56 ± 1.38 0.157
C22:4 n-6 0.34 ± 0.11 0.28 ± 0.24 0.25 ± 0.11 0,068
C22:5 n-6 0.15 ± 0.06a 0.13 ± 0.05b 0.14 ± 0.05a,b <0.001
n-3 2.84 ± 0.89a 3.33 ± 1.08b 3.02 ± 0.96a,b <0.001
C18:3 n-3 0.21 ± 0.07 0.22 ± 0.08 0.21 ± 0.06 0.193
C20:5 n-3 0.36 ± 0.32a 0.47 ± 0.40b 0.42 ± 0.36a,b 0.010
C22:5 n-3 0.33 ± 0.10 0.35 ± 0.09 0.35 ± 0.11 0.537
C22:6 n-3 1.94 ± 0.58a 2.28 ± 0.67b 2.04 ± 0.62a,b <0.001
n-6/n-3 ratio 18.45 ± 5.21a 15.48 ± 5.22b 15.76 ± 4.66b 0.038
Values expressed as mean ± SD. Different superscript letters means that differences
are statistically different, p < 0.05 in a general linear model with Bonferroni post-
hoc correction. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids;











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































YCLNU2972_proof ■ 15 November 2016 ■ 4/8they belonged. First, plasma n-6 PUFAs decreased (p < 0.05), except
plasma arachidonic acid (C20:4 n-6) and C22:4 n-6. Second, total
plasma n-3 PUFAs (p < 0.001) and, the main n-3 long-chain poly-
unsaturated FAs (LC-PUFAs), EPA and DHA increased significantly
(p < 0.01). Consequently, the n-6/n-3 ratio decreased (p < 0.05). At
the end of the program, total MUFA and oleic acid levels were still
higher than baseline values, while levels of stearic acid, total n-6
PUFA, linoleic acid (C18:2 n-6, LA) and C18:3 n-6 and the n-6/n-3
ratio continued to decrease. By contrast, myristic acid, C20:2 n-6,
C22:5 n-6 and n-3 PUFAs presented intermediate levels between
baseline and two months.
The relationships between plasma FAs (only those that changed
significantly during the treatment) and the anthropometric and
biochemical parameters of the population at two months are
shown in Table 3. It was observed that the decrease in plasma
myristic acid was associated with a reduction in cholesterol (0.608,
p < 0.001), HDL cholesterol (0.326, p < 0.05), LDL cholesterol (0.397,
p < 0.05), apoB (0.494, p < 0.05) and insulin (1.151, p < 0.05). The
increase in plasma MUFAs, especially C18:1n-9, was inversely
associated with weight (0.340, p < 0.05), body fat (0.399,
p < 0.05), fat mass index (0.329, p < 0.05), glucose (0.338,
p < 0.05) and HDL cholesterol (0.320, p < 0.05). Regarding plasma
PUFAs, the variations in n-3 series FAs were not associated with any
of the factors studied, whereas the reduction in n-6 PUFAs was
directly related to weight, body fat, glucose (p < 0.05), cholesterol
(p < 0.01), HDL cholesterol and apoA1 (p < 0.05), but its association
with diastolic blood pressure (DBP) was negative (0.288,
p < 0.05). In addition, the reduction in the n-6/n-3 ratio was
positively correlated with HDL cholesterol (0.329, p < 0.05) and
apoA1 (0.475, p < 0.05).
At six months of treatment (Table 4), in contrast to two months,
total plasma MUFAs and oleic acid presented no relationship with
any of the adiposity anthropometric indicators or cardiometabolicTa A
s
St M fa G A
1 130
Please cite this article in press as: Guerendiain M, et al., Changes in plasma fatty acid composition are associated with improvements in obesity
and related metabolic disorders: A therapeutic approach to overweight adolescents, Clinical Nutrition (2016), http://dx.doi.org/10.1016/
j.clnu.2016.11.006
Table 4
Associations between changes in plasma fatty acids and variations in clinical and biochemical parameters at 6 months of treatment.
Parametersa C18:0 MUFA C18:1n-9 C20:1n-9 PUFA C20:3n-9 n-6 PUFA C18:2n-6 C18:3n-6 C20:3n-6 n-6/n-3 ratio
Weight 0.155 0.100 0.058 0.052 0.033 ¡0.352* 0.022 0.031 0.010 0.013 0.031
BMI 0.119 0.072 0.039 0.014 0.025 0.330 0.050 0.104 0.082 0.051 0.055
SDS-BMI 0.067 0.011 0.031 0.083 0.037 ¡0.377* 0.059 0.093 0.080 0.029 0.062
WC 0.056 0.005 0.035 0.127 0.068 0.177 0.000 0.016 0.012 0.009 0.094
% FM 0.026 0.029 0.081 0.141 0.068 ¡0.457* 0.102 0.183 0.122 0.028 0.036
FM 0.141 0.083 0.032 0.006 0.004 ¡0.417* 0.021 0.097 0.070 0.013 0.016
FMI 0.124 0.078 0.027 0.032 0.017 ¡0.420* 0.057 0.134 0.129 0.032 0.057
FFM 0.026 0.029 0.081 0.141 0.068 0.457* 0.102 0.183 0.122 0.028 0.036
SBP 0.040 0.112 0.126 0.252 0.091 0.149 0.058 0.004 0.124 0.035 0.033
DBP 0.086 0.179 0.200 0.151 0.169 0.114 0.096 0.056 0.105 0.014 0.149
Insulin 0.338 0.617 0.618 0.549 1.143 0.669 0.977* 0.978* 0.593 0.279 0.927*
Cholesterol 0.197 0.059 0.069 0.182 0.048 0.206 0.126 0.279 0.272 0.067 0.498*
HDL-C 0.355 0.170 0148 0.004 0.028 0.100 0.152 0.311 0.270 0.165 0.472*
LDL-C 0.124 0.175 0.175 0.077 0.119 0.078 0.262 0.344 0.165 0.052 0.439*
TAG 0.065 0.376 0.319 ¡0.399* ¡0.427* ¡0.587** 0.328 0.209 0.186 0.093 0.087
ApoA1 0.078 0.019 0.094 0.761* 0.247 0.148 0.282 0.340 0.091 0.126 0.585*
ApoB 0.205 0.331 0.400 0.146 0.209 0.214 0.243 0.191 0.165 0.297 0.213
CRP 0.377 0.131 0.002 0.167 0.221 0.265 0187 0.262 0.063 0.223 0128
Standardized regression coefficients adjusted for age, sex, SDS-BMI and Tanner stages at baseline, degree of physical activity and changes in lipids and energy intake at 6
months; *p < 0.05, **p < 0.01, ***p < 0.001 (linear regression model). Q4
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. Weight (Kg), n¼ 32; BMI, body mass index (Kg/m2), n¼ 31; SDS-BMI, standard deviation score of BMI,
n¼ 31;WC, waist circumference (cm), n¼ 31; %FM, fat mass percentage, n¼ 31; FM, absolute fat mass (kg), n¼ 30; FMI, fat mass index (Kg/m2), n¼ 30; FFM, fat free mass (%),
n¼ 31; SBP, systolic blood pressure (mmHg), n¼ 30; DBP, diastolic blood pressure (mmHg), n¼ 30; Insulin (mUI/L), n¼ 12; Cholesterol (mmol/L), n¼ 31; HDL-C, high-density
lipoprotein cholesterol (mmol/L), n ¼ 31; LDL-C, low-density lipoprotein cholesterol (mmol/L), n ¼ 31; TAG, triacylglycerol (mmol/L), n ¼ 31; ApoA1, apolipoprotein A1 (mg/
dL), n ¼ 19; ApoB, apolipoprotein B (mg/dL), n ¼ 19; CRP, C-reactive protein (mg/L), n ¼ 19.
a Changes in parameters between the baseline and 6 months of treatment.



































































































































YCLNU2972_proof ■ 15 November 2016 ■ 5/8risk factors. However, an association was found between the in-
crease in plasma C20:1 n-9 and TAG (0.399, p < 0.05) and apoA1
(0.761, p < 0.05). Moreover, the reduction in total PUFAs was
inversely related to TAG (0.427, p < 0.05), while the decreases in
the n-6 series (total n-6 PUFAs and LA) were directly associated
with insulin (p < 0.05). With regard to the reduction in the n-6/n-3
ratio, the relationships that were identified with insulin (0.927,
p < 0.05), cholesterol (0.498, p < 0.05), HDL (0.472, p < 0.05) and
LDL (0.439, p < 0.05) cholesterol and apoA1 (0.585, p < 0.05) were
positive. Interestingly, the increase in plasma C20:3 n-9 was asso-
ciated with a reduction in weight (0.352, p < 0.05), SDS-BMI
(0.377, p < 0.05), fat mass percentage (0.457, p < 0.05), kg of
fat mass (0.417, p < 0.05), fat mass index (0.420, p < 0.05) and
TAG (0.587, p < 0.05), as well as a rise in fat-free mass (0.457,
p < 0.05).
Figure 1 shows the changes in plasma FA composition according
to the degree of weight loss in the adolescents, defined as the
reduction in SDS-BMI at the end of the intervention. It was estab-
lished that those who had a reduction in SDS-BMI greater than 0.5
presented the highest changes in plasma FA composition and the
most significant differences with respect to the baseline. Thus, this
group presented a significant reduction in levels of stearic acid
(p¼ 0.009), total n-6 PUFA (p¼ 0.043), linoleic acid (p¼ 0.049) and
C18:3n-6 (p ¼ 0.011) at six months of treatment compared to basal
conditions, whereas total MUFA (p ¼ 0.024) and oleic acid
(p ¼ 0.016) levels showed the opposite behavior. When comparing
the values of each plasma FA between the three weight loss groups,
differences were observed for myristic acid (p ¼ 0.031), with the
values detected for the reduction SDS-BMI > 0.5 group being lower
than those of the intermediate group (reduction SDS-BMI 0.25-0.5).
4. Discussion
The plasma fatty acid composition of the adolescents under
study changed during the intervention, which is consistent with
other variations considered favorable for obesity prevention and/or
treatment. It may be assumed that the reduction in plasma SFA
could be a beneficial effect, since these FA are considered toPlease cite this article in press as: Guerendiain M, et al., Changes in plasm
and related metabolic disorders: A therapeutic approach to overweig
j.clnu.2016.11.006promote obesity problems and preserve fat mass even after weight
loss [15]. On the other hand, MUFA C18:1n-9 and C20:1n-9 plasma
content increased, a finding reported by other authors as inversely
related to overweight status [10]. With regard to PUFAs, the
observed reduction in the plasma n-6 series and the increase in n-3
levels, especially EPA and DHA, lead to a reduction in the n-6/n-3
ratio and have also been linked in the literature to a lower preva-
lence of obesity and CVD risk factors [7,16]. However, unexpectedly,
C20:4 n-6 and C22:4 n-6, which are the precursors of the biosyn-
thesis of dihomo-prostaglandin derivatives [17], remained un-
changed. It has been described that a high arachidonic acid intake
leads to proliferation and differentiation of wait adipose tissue,
lower fatty acids oxidation, and insulin and leptin resistance [18].
Also, their metabolites (prostaglandin 2, thromboxane 2 and
leukotriene 4) are prothrombotic and proinflammatory effects.
The tendency observed during the second period of intervention
of plasma C14:0, C20:2n-6, C22:5n-6, total n-3 PUFAs, EPA and DHA
to return to baseline values could be explained by the lower fre-
quency of medical controls. Thus, the recovery of inappropriate
eating habits as a result of reduced observation could be respon-
sible for this step back.
A recent study [19] analyzed tertiles of SFA intake in adolescents
undergoing interdisciplinary therapy. The authors indicated that
the individuals with a greater reduction in FAs presented decreased
levels of insulin, insulin resistance and total and LDL cholesterol. In
line with this study and other work [20], we observed that the
changes in the different fractions of cholesterol (total cholesterol,
HDL and LDL) and fasting insulin were linked to the lower plasma
levels of myristic acid. It should be noted that, although other au-
thors did not find any associations between SFAs and apolipopro-
teins, we observed a direct link with apolipoprotein B. This finding
may be useful, because apoB is proatherogenic and is a better
predictor of cardiovascular risk than LDL cholesterol and other
conventional lipids [21].
Cross-sectional and longitudinal studies have concluded that
Mediterranean diets, especially those that include oleic acid, play
an important role in body weight maintenance and obesity pre-
vention [10,22,23]. It has been proposed that MUFAs promote lipida fatty acid composition are associated with improvements in obesity











































Fig. 1. Changes in plasma fatty acid composition according to degree of weight loss at 6 months. Changes in plasma fatty acids between baseline and 6 months as defined by a
reduction in standard deviation score of body mass index (SDS-BMI). Values expressed as means ± SEM. Models were adjusted for sex, age, SDS-BMI, Tanner stage, degree of
physical activity and the corresponding fatty acid at baseline, and changes in energy and fat intake at 6 months. Bars with different superscript letters are significantly different from
each other, p < 0.05 in a general linear model (GLM) with Bonferroni post-hoc correction; *statistically significant differences for values between 6 months and baseline, p < 0.05 in
a GLM. Means of C15:0, C18:3 n-6 and C18:3 n-3 were multiplied by 10. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. N ¼ 7/11/
18 for groups SDS-BMI<0.25, SDS-BMI ¼ 0.25e0.5 and SDS-BMI>0.5, respectively.



































































































































YCLNU2972_proof ■ 15 November 2016 ■ 6/8oxidation [22] and decrease lipogenesis, which leads to reduced
weight and adiposity [7]. However, it is possible that the effect of
C18:1 n-9 will be due to the displacement of deleterious properties
of SFA than to its own action [24]. Hence, as expected, during the
intensive phase of the treatment, it was observed that the increase
in these FA levels was related to a decline in adiposity, which was
defined by weight, fat mass and fat mass index. Further studies are
required to determine if changes in plasma MUFA, mainly as oleic
acid, could have a beneficial effect on body composition in
adolescents.
Regarding MUFAs and cardiovascular risk markers, the evidence
is controversial. In a review andmeta-analysis, Schwingshackl et al.
[23] did not observe differences in HDL and LDL cholesterol or TAG
in individuals subjected to a controlled diet with different MUFA
levels. However, other authors have established that these FAs lead
to lower LDL [25] or higher HDL cholesterol [26]. In our study,
plasma MUFA levels were associated with a reduction in TAG and
HDL concentration. By contrast, the rise in plasma C20:1 n-9 was
related to an increase in apoA1, which is a lipoprotein that exerts an
antiatherogenic effect [2]. On the other hand, the evidence suggests
that MUFAs are implicated in a lower prevalence of type-2 diabetes
[10], a common disease among people who are obese [2,3]. Pre-
cisely, we found that oleic acid and total MUFA plasma levels are
related to glucose concentration decrease in adolescents.Please cite this article in press as: Guerendiain M, et al., Changes in plasm
and related metabolic disorders: A therapeutic approach to overweig
j.clnu.2016.11.006As expected, we found that the reduction in total n-6 PUFA
levels and linoleic acid in plasma was associated with a decrease in
weight and fat mass. It has been reported that LA intake, which
leads to arachidonic acid synthesis [16], is related to a higher
expression of the genes involved in lipogenesis [27]. In mice fed
diets modeled on the 20th-century changes in human LA con-
sumption, Alvheim et al. demonstrated that these variations in-
crease the endocannabinoids associated with higher food intake,
feed efficiency and adiposity [16].
With regard to the cardiometabolic profile, we observed that a
reduction in plasma LA was associated with a reduction in HDL
cholesterol and apoA1, in line with a previous study [28]. We also
found that changes in C18:3n-6 (g-linolenic acid) plasma levels
were directly related to cholesterol [6], which was beneficial in this
case because g-linolenic acid levels decreased. Moreover, our
findings and those of other authors [23] suggest that changes in
plasma n-6 PUFAs are linked to a reduction of diastolic blood
pressure in overweight individuals. These results led us to conclude
that plasma n-6 PUFAs should be studied in depth, since FAs
belonging to the same series may present positive or negative as-
sociation with cardiometabolic risk markers.
An elevated intake of n-6 PUFAs or diets with a high n-6/n-3
ratiomay affect the cell membrane composition of adult individuals
by decreasing membrane n-3 PUFAs [29]. Moreover, it has beena fatty acid composition are associated with improvements in obesity
ht adolescents, Clinical Nutrition (2016), http://dx.doi.org/10.1016/
Q1



































































































































YCLNU2972_proof ■ 15 November 2016 ■ 7/8reported that an increase in insulin concentration and resistance is
linked to an elevated n-6/n-3 ratio and thus affects insulin sensi-
tivity. In our case, the reduction in total n-6 PUFA and LA plasma
levels was related to decline in fasting insulin and glucose con-
centrations observed during the therapy. We consider that this
finding may be important due to the current high prevalence of
diseases related to hyperinsulinemia and insulin resistance such as
type-2 diabetes, a comorbidity related to obesity, even in adoles-
cence [3].
On the other hand, plasma C20:3 n-9 was correlated to body
fatness at 6 months. When the FA increased, the anthropometric
indicators of general adiposity had the opposite trend. To our
knowledge, these relationships have not been studied in depth and
there are no studies that explore the possible causes or mecha-
nisms of our findings. However, considering the definition of
essential FA deficiency [30], it could be hypothesized that this as-
sociation is linked to the lower C18:2 n-6 plasma level, since the
increase of C20:3 n-9 was accompanied by a decrease of the linoleic
acid. Moreover, given that the C20:3 n-9 is synthetized from C18:1
n-9 and, precisely, oleic acid increased at six months, it should be
explored if this relationship is due to the biosynthesis.
In terms of weight loss, the SDS-BMI > 0.5 group presented the
greatest changes in plasma FA composition by the end of the pro-
gram, as expected. Our study indicates that the overweight and
obese adolescents who lost most weight had significant changes in
plasma fatty acids. The main variations were observed in n-6 PUFAs
and MUFAs, whereas n-3 FAs remained unaltered in all weight loss
groups. Interestingly, the reduction in plasma myristic acid and n-6
PUFAs and the increase in oleic acid and total MUFAs in plasma
were linked to a higher ponderal decrease. These results may be
useful for future projects aimed to develop obesity treatments for
adolescents. However, the data need to be confirmed by more
complete studies, since we did not obtain similar findings in obese
children, adolescents or adults.
The main limitation of this study is the absence of a control
group. However, we consider that by taking into account the
baseline values for each subject and focusing on the evolution of
each parameter, we were able to establish some preliminary con-
clusions that could prove very useful in larger-scale interventional
studies in the future.
The combined study of the variations in plasma FA, anthropo-
metric parameters and cardiometabolic profile at different stages
helped shed light on the links between those variables and the
effectiveness of the anti-obesity program. The relationships
analyzed may be used as tools in the study of adiposity and car-
diometabolic profile in adolescents.
In conclusion, we found that the modification in plasma fatty
acid composition, especially n-6 PUFAs, MUFAs and myristic acid, is
related to changes in adiposity and cardiometabolic risk factors in
anti-obesity programs aimed at adolescents.
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